NASDAQ: RENECartesian Growth Corp Ii Stock
$11.20+0.02 (+0.18%)
Updated Apr 23, 2024
RENE Price
$11.20
Fair Value Price
-$0.14
Market Cap
$242.15M
52 Week Low
$10.52
52 Week High
$11.92
P/E
27.32x
P/B
-13.06x
P/S
N/A
PEG
0.53x
Dividend Yield
N/A
Revenue
$0.00
Earnings
$11.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.02
Operating Cash Flow
-$923k
Beta
-0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RENE Overview
Cartesian Growth Corporation II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.
Zen Score
–
Industry Average (8)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RENE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RENE ($11.20) is overvalued by 8,006.9% relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RENE ($11.20) is not significantly undervalued (8,006.9%) relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RENE ($11.20) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RENE due diligence checks available for Premium users.
Be the first to know about important RENE news, forecast changes, insider trades & much more!
RENE News
Valuation
RENE fair value
Fair Value of RENE stock based on Discounted Cash Flow (DCF)
Price
$11.20
Fair Value
-$0.14
Undervalued by
8,006.90%
RENE ($11.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RENE ($11.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RENE ($11.20) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RENE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.32x
Industry
35.77x
Market
41.92x
RENE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RENE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
RENE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-13.06x
Industry
-14.4x
RENE price to earnings growth (PEG)
For valuing profitable companies with growth potential
RENE is good value based... subscribe to Premium to read more.
PEG Value Valuation
RENE's financial health
Profit margin
Revenue
$0.0
Net Income
$2.1M
Profit Margin
0%
RENE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$174.6M
Liabilities
$18.9M
Debt to equity
-1.02
RENE's short-term liabilities ($1.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RENE's long-term liabilities ($17.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RENE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RENE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$476.0k
Investing
$77.1M
Financing
-$76.6M
RENE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RENE vs Shell Company Stocks
Cartesian Growth Ii Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.